BACKGROUND Chronic heart failure(CHF)is a serious and prevalent condition characterized by impaired cardiac function and inflammation.Standard therapy for CHF has limitations,prompting the exploration of alternative t...BACKGROUND Chronic heart failure(CHF)is a serious and prevalent condition characterized by impaired cardiac function and inflammation.Standard therapy for CHF has limitations,prompting the exploration of alternative treatments.Recombinant human brain natriuretic peptide(BNP)has emerged as a potential therapy,with evidence suggesting that it can improve cardiac function and reduce inflammation in patients with CHF.However,further research is required to determine the efficacy and safety of lyophilized recombinant human BNP in CHF patients and its impact on microinflammatory status.This study aimed to investigate the effects of lyophilized recombinant human BNP therapy on CHF patients’cardiac function and microinflammatory status.AIM To investigate the effects of freeze-dried recombinant human BNP therapy on cardiac function and microinflammatory status in patients with CHF.METHODS In total,102 CHF patients admitted to our hospital from January 2021 to January 2022 were randomly assigned to control and observation groups(n=51 patients/group).The control patients were treated with standard HF therapy for 3 d,whereas the observational patients were injected with the recombinant human BNP for 3 d.Clinical efficacy,inflammatory factor levels,myocardial damage,cardiac function before and after the treatment,and adverse reactions during treatment were compared between the two groups.RESULTS The overall clinical efficacy was higher in the observation group than in the control group.Compared with baseline,serum hypersensitive C-reactive protein,N-terminal proBNP,and troponin I level,and physical,emotional,social,and economic scores were lower in both groups after treatment,with greater reductions in levels and scores noted in the observation group than in the control group.The overall incidence of adverse reactions in the observation group was not significantly different compared with that in the control group(P>0.05).CONCLUSION Freeze-dried recombinant human BNP therapy can improve heart function and enhance microinflammatory status,thereby improving overall quality of life without any obvious side effects.This therapy is safe and reliable.展开更多
目的:对冻干重组人脑利钠肽联合厄贝沙坦氢氯噻嗪片在急性心力衰竭(acute heart failure,AHF)伴高血压中的抢救效果及对N末端前体脑利钠肽(N terminal pro B type natriuretic peptide,NT-proBNP)水平变化的影响进行分析,进一步探寻其在...目的:对冻干重组人脑利钠肽联合厄贝沙坦氢氯噻嗪片在急性心力衰竭(acute heart failure,AHF)伴高血压中的抢救效果及对N末端前体脑利钠肽(N terminal pro B type natriuretic peptide,NT-proBNP)水平变化的影响进行分析,进一步探寻其在AHF伴高血压病患中的抢救效果和对NT-proBNP水平的影响。方法:选取2020年4月—2021年12月襄城县人民医院心内科收治的97例AHF伴高血压患者作为研究对象,按随机数表法将患者分为对照组(n=43)和观察组(n=54),其中对照组采用口服厄贝沙坦氢氯噻嗪片治疗,观察组在对照组基础上联合冻干重组人脑利钠肽治疗。对比两组患者抢救总有效率、康复和临床指标、心脏彩超结果以及不良反应发生率。结果:治疗后,观察组的抢救总有效率为94.44%,高于对照组的86.05%,差异有统计学意义(χ^(2)=3.998,P<0.05);治疗后,观察组的康复指标状况较对照组更佳,差异有统计学意义(t=4.268、9.168、12.574,P<0.05);治疗后,两组患者的临床指标较治疗前更低,且观察组的NT-proBNP、糖类抗原125 (carbohydrate antigen 125,CA-125)、伴乳凝素-3 (galectin 3,Gal-3)、心肌肌钙蛋白I (cardiac troponin I,CTN I)水平较对照组更低,差异有统计学意义(t=16.291、4.633、7.556、6.041,P<0.05);治疗后,两组患者的心脏彩超结果较治疗前更高,且观察组的左室射血分数(left ventricular ejection fractions,LVEF)、每搏输出量(stroke volume,SV)、计算心输出量(calculation of cardiac output,CO)、心脏指数(cardiac index,CI)较对照组更高,差异有统计学意义(t=5.205、3.005、3.913、8.045,P<0.05);治疗后,观察组的不良反应发生率较对照组更低,差异有统计学意义(χ^(2)=13.488,P<0.05)。结论:冻干重组人脑利钠肽联合厄贝沙坦氢氯噻嗪片在AHF伴高血压中的抢救效果较好,能够改善病患心功能,降低NT-proBNP水平,且药副作用小。展开更多
文摘BACKGROUND Chronic heart failure(CHF)is a serious and prevalent condition characterized by impaired cardiac function and inflammation.Standard therapy for CHF has limitations,prompting the exploration of alternative treatments.Recombinant human brain natriuretic peptide(BNP)has emerged as a potential therapy,with evidence suggesting that it can improve cardiac function and reduce inflammation in patients with CHF.However,further research is required to determine the efficacy and safety of lyophilized recombinant human BNP in CHF patients and its impact on microinflammatory status.This study aimed to investigate the effects of lyophilized recombinant human BNP therapy on CHF patients’cardiac function and microinflammatory status.AIM To investigate the effects of freeze-dried recombinant human BNP therapy on cardiac function and microinflammatory status in patients with CHF.METHODS In total,102 CHF patients admitted to our hospital from January 2021 to January 2022 were randomly assigned to control and observation groups(n=51 patients/group).The control patients were treated with standard HF therapy for 3 d,whereas the observational patients were injected with the recombinant human BNP for 3 d.Clinical efficacy,inflammatory factor levels,myocardial damage,cardiac function before and after the treatment,and adverse reactions during treatment were compared between the two groups.RESULTS The overall clinical efficacy was higher in the observation group than in the control group.Compared with baseline,serum hypersensitive C-reactive protein,N-terminal proBNP,and troponin I level,and physical,emotional,social,and economic scores were lower in both groups after treatment,with greater reductions in levels and scores noted in the observation group than in the control group.The overall incidence of adverse reactions in the observation group was not significantly different compared with that in the control group(P>0.05).CONCLUSION Freeze-dried recombinant human BNP therapy can improve heart function and enhance microinflammatory status,thereby improving overall quality of life without any obvious side effects.This therapy is safe and reliable.
